logo
Plus   Neg
Share
Email

Black Knight Q2 Profit Tops Estimates; Expects FY Adj. EPS At Low End Of Outlook

Black Knight, Inc. (BKI) reported that its second-quarter adjusted earnings per share increased 7 percent to $0.49 from $0.46, prior year. On average, 14 analysts polled by Thomson Reuters expected the company to report profit per share of $0.48, for the quarter. Analysts' estimates typically exclude special items.

Second-quarter adjusted revenues increased 6 percent to $295.1 million compared to $277.4 million, last year. Analysts expected revenue of $296.19 million for the quarter.

For the full year, the company now expects adjusted earnings per share to be at the low end of the prior guidance range of $1.90 to $2.00. Revenues are expected to be at the low end of the prior guidance range of $1.18 billion to $1.20 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $1.97 on revenue of $1.19 billion.

Black Knight CEO Anthony Jabbour said: "While our performance through the first half of the year was in line with our expectations, we have updated our full year 2019 outlook to reflect an earlier than planned client deconversion that was the result of a decision we made to no longer support a non-core, single-client platform."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT